ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FAB Fusion Antibodies Plc

4.875
0.325 (7.14%)
Last Updated: 15:41:57
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.325 7.14% 4.875 1,940,856 15:41:57
Bid Price Offer Price High Price Low Price Open Price
4.50 5.25 5.25 4.25 4.55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0998 -0.51 1.33M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:24:47 O 19,188 5.20 GBX

Fusion Antibodies (FAB) Latest News

Fusion Antibodies (FAB) Discussions and Chat

Fusion Antibodies Forums and Chat

Date Time Title Posts
05/12/202315:27☆ Fusion Antibodies: from discovery to Clinical supply ☆3,669
28/11/202316:25NEW FAB Fusion Antibodies The Next AVCT64
18/9/202014:23Fusion Antibody II51
17/9/202008:25COVID. RAPID PROGRESS MADE. Ј3M RAISED58
08/2/201221:34Fabio Capello Resigns.......9

Add a New Thread

Fusion Antibodies (FAB) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:24:485.2019,188997.78O
16:24:125.14974.99O
16:22:435.143,752192.85O
16:21:425.1038,0381,939.94O
16:21:084.9537,6791,865.11O

Fusion Antibodies (FAB) Top Chat Posts

Top Posts
Posted at 05/12/2023 08:20 by Fusion Antibodies Daily Update
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 4.55p.
Fusion Antibodies currently has 26,014,946 shares in issue. The market capitalisation of Fusion Antibodies is £1,331,965.
Fusion Antibodies has a price to earnings ratio (PE ratio) of -0.51.
This morning FAB shares opened at 4.55p
Posted at 04/12/2023 08:18 by luckyabbeygale
That is lies. I have tried to buy fab on a spread bet using spread x or with ig index for over a year now. They both say it is closing only.
Posted at 04/12/2023 08:12 by jaknife
luckyabbeygale,

"No one is going to put in their ig user name and password just for you to hack their account."

That is the IG page for FAB, which clearly contradicts your claim in post 3,653 that

"No one holds this stock on a spread bet or on a cfd."

JakNife
Posted at 30/11/2023 14:40 by thiopia
Googling 'Mammalian Cell Display' brings up the name of a long time academic researcher on the area dating back to 2009 in terms of published research... Mitchell Ho

Guess who is the Director of the Research on Antibody Engineering (Mammalian Cell Display) at US NCI and on the Fusion Antibodies FAB RNS ? Mitchell Ho !!!

I think people are underestimating just how big a deal this could be for FAB

US Govt NCI just provides one level of validation but an important on (as well as having a multi-billion budget) but this should lead to lots of Bios and Pharmas also beating a path to FAB's door
Posted at 28/11/2023 17:53 by fillipe
FAB raised abt £1.56m in May/June this year (2023).
It was an issue of 33.439m shares at a rock-bottom price of only 5p and the reason was the need for capital.

f.
Posted at 28/11/2023 15:25 by andymunchkin
superg118 Sep '20 - 11:01 - 217 of 3633
0 2 1
Tidy

FAB is not yet on the map as such but will be in the coming week or so.

Most booing in now won;t have adman clue about FAB they will assume big cash needed which is completely wrong. That's what I love about FAB.

Very low risk, very big upside...
----
price was 1.2op & itCrashed like crUshed candIes pmsl lYingCnTs
Posted at 09/11/2023 10:00 by mr macgregor
Mr MacGregor - 27 Feb 2022 - 17:20:23 - 2149 of 3332

Whatsthepoint is certainly well named, and an idiot as evidenced by holding shares in this donkey. Simon Douglas poundshop chairman of FAB and ODX, CEOs a blur. Massive red flags. You have been warned.
Posted at 03/10/2023 11:15 by soultrading
#FAB mcap is £3.4m and the company currently has c.£1m in cash.

So its EV is in the region of £2.4m. Which is way too cheap!

In my view, the company is a much better run entity now. It has some work to do but this share price is a real gift.

It is in the final stages of a second Ai partnership and has already seen and stated that in the past few months, the Company has enjoyed an uplift in business & purchase orders have been received.

A three fold uplift since the start of 2023, it really could be one of those companies that injects a lot of profit into retail hands.

Interview tomorrow too. If you are on the sidelines I would take a starter now.
Posted at 31/7/2023 10:18 by jaknife
soultrading,

"FAB Looks very strong"

Could you extrapolate that into a longer sentence please or perhaps a paragraph? What in particular makes FAB look "very strong"?

1. Is it the last set of results that revealed ongoing losses that were material relative to the balance sheet?

2. Was it the manner in which the company was forced into a desperate fund raising at a mere 5p, which represented an 84% discount to the prevailing share price?

3. Was it how the retail offer raised a pathetic £113k from retail shareholders despite the massive discount, indicating a huge lack of interest from retail punters?

4. Is it the cash burn numbers which show that FAB raised £1.7m in the placing when the annual cash burn is £2.2m?

5. Is it that the finals to the year ending 31 March are due soon and will highlight all of the above?

JakNife
Posted at 20/5/2023 19:36 by hedgehog 100
What is fair value for FAB at the moment?

Let's try some robust valuation analysis.


Assuming full subscription for the 41,171,746 fundraising shares, added to existing 26,014,946 shares, then FAB will have 67,186,692 shares in issue. At 5p/share that would be a market cap. of c. £3.6M.; and c. £4.956M. at the current share price of 7.375p.

The company's H1 cash-burn was £800K., and the net fundraising cash if full subscription will be c. £1.42M.

It plans to cut costs, but revenue is collapsing: down massively to min. £2.8M. in 2023, but with about two thirds of that in H1.

So current annualised revenue based on H2 is probably below £2M., and the cash looks like it will probably be burnt within a year.

The CRO sector is very fragmented and competitive, and with reduced investment in the broader biotech sector, margins could come under pressure, to compound falling revenues.

From Wikipedia:-

" ... Organizations who have had success in working with a particular CRO in a particular context (e.g. therapeutic area) might be tempted or encouraged to expand their engagement with that CRO into other, unrelated areas; however, caution is required as CROs are always seeking to expand their experience and success in one area cannot reliably predict success in unrelated areas that might be new to the organization.[5] ...

As of 2013, there were over 1,100 CROs in the world, despite continued trends toward consolidation. Many CROs have been acquired while others have gone out of business.[9] ..."




By way of comparison with what you could get elsewhere for a market cap. of £5M., NWT (market cap. £5.015M.at 53.5p) announced a positive trading update this week:-

17/05/2023 07:00 UK Regulatory (RNS & others) Newmark Security PLC Year-end trading update LSE:NWT Newmark Security Plc

"Continued revenue growth and a return to profitability

Newmark Security plc (AIM: NWT), a leading provider of electronic, software and physical security systems, today provides an update on trading for the year ended 30 April 2023 ("FY23"), reaffirming the Company's return to profitability. ..."



NWT's FY revenue is expected to be £20M.+, & pre-tax profit £1M.+.

It's outlook is buoyant, and there's plenty of business for everyone.
Posted at 20/5/2023 09:40 by hedgehog 100
JakNife 6 Apr '23 - 18:29 - 3279 of 3333 0.010000 4 1
"Here's another hugely dilutive placing that's been agreed in the sector:

It's a chunky raise but at 1p it's an 84% discount to the closing price before it was previously suspended.
All arrows point to a fund raise for FAB that materially dilutes current shareholders.
JakNife"

Well done to JakNife ... his AGY example was even the precise % discount as FAB's.


dave454519 May '23 - 10:15 - 3283 of 3333 0 1 1
"Bloody hell that is savage.
At least they did not have the nerve to say they were "pleased" to announce"

Not in yesterday's first RNS Dave, but they still managed to get in two 'pleased to say/announce' yesterday:-

19/05/2023 10:00 UK Regulatory (RNS & others) Fusion Antibodies PLC Placing, Subscription and Retail Offer LSE:FAB Fusion Antibodies Plc
" ... Fusion Antibodies CEO, Adrian Kinkaid said : "We are pleased to say that we have been able to raise funds in an extremely challenging market, ..." ..."


19/05/2023 10:01 UK Regulatory (RNS & others) Fusion Antibodies PLC REX Retail Offer LSE:FAB Fusion Antibodies Plc
"Fusion Antibodies plc (AIM: FAB) is pleased to announce a retail offer via REX (the "REX Retail Offer") of ordinary shares ("Ordinary Shares") of 4 pence each in the capital of the Company (the "REX Retail Offer Shares")
... The issue price of the Placing Shares and Subscription Shares is 5 pence (the "Issue Price"). The price of the REX Retail Offer Shares is equal to the Issue Price. ..."



volsung 19 May '23 - 10:20 - 3288 of 3333 0 0 1
"Not the best Belfast share"

No, but the tiny number of London-listed N.I. shares includes former 15-bagger Kainos (KNOS) (still currently an 8.8-bagger from its 2015 IPO price of 139p); and FD Technologies (FDP) - currently a 37.6-bagger from its 2002 IPO price of 50p.

See the "Rockpool Acquisitions (ROC)" thread for details (it's a Northern Ireland shell company currently arranging a RTO):-
Fusion Antibodies share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com